For a patient on weekly semaglutide (shrapitide) 7.5 mg, occasional lorazepam 0.5 mg PRN, daily metoprolol succinate with a pacemaker who experiences palpitations and pressure sensation when a metoprolol dose is missed, should the shrapitide dose be continued, lorazepam use limited, metoprolol adherence emphasized, pacemaker settings evaluated, and is dronedarone (Multaq) appropriate to add?

Immediate Recommendations for This Patient

The patient should continue semaglutide at 7.5 mg weekly, strictly adhere to metoprolol dosing within the 24-hour window, undergo urgent pacemaker interrogation and settings evaluation, and dronedarone (Multaq) should NOT be added to this regimen. The lorazepam use pattern (5-6 times monthly) is acceptable for breakthrough symptoms but requires investigation of the underlying cause of palpitations.

Critical Safety Concern: Dronedarone is Contraindicated

Dronedarone (Multaq) should not be used in this patient for rate control. The 2014 AHA/ACC/HRS guidelines explicitly state that dronedarone should not be used to control ventricular rate in patients with permanent AF as it increases the risk of stroke, myocardial infarction, systemic embolism, or cardiovascular death 1, 2, 1, 2. The FDA label confirms dronedarone is contraindicated in patients with permanent AF and those with symptomatic heart failure 3. While this patient's AF status isn't fully clarified, the presence of a pacemaker and ongoing palpitations requiring rate control suggests a chronic arrhythmia burden that makes dronedarone inappropriate.

Metoprolol Management: The Core Issue

The patient's symptoms occurring at the 22-hour mark (before the 24-hour dosing interval) indicate subtherapeutic beta-blockade and require immediate attention. This is the primary driver of his palpitations and pressure sensation under the pacemaker.

Algorithmic Approach to Metoprolol Optimization:

1. Verify current metoprolol formulation and dose - The patient appears to be on metoprolol succinate (extended-release), which has a 24-hour duration 4

2. If symptoms persist at 22 hours:

   • Consider splitting to twice-daily dosing with metoprolol tartrate (immediate-release formulation)
   • Alternative: Increase the once-daily metoprolol succinate dose
   • Target resting heart rate <80 bpm per guidelines 2, 1

3. Assess for drug interactions - Dronedarone increases metoprolol bioavailability in CYP2D6 extensive metabolizers 5, which is another reason NOT to add it

4. Monitor for:

   • Bradycardia (heart rate <50 bpm is concerning per FDA label 4)
   • Worsening heart failure symptoms
   • Exercise intolerance

Pacemaker Evaluation: Non-Negotiable

The pressure sensation under the left clavicle pacemaker site combined with palpitations when metoprolol wears off mandates urgent pacemaker interrogation. This evaluation should assess:

• Pacing thresholds and lead integrity - Pressure sensation may indicate lead-related issues
• Arrhythmia burden quantification - Modern pacemakers can measure AF burden 6
• Rate response settings - May need adjustment if patient has chronotropic incompetence
• Mode switch episodes - Indicates paroxysmal AF episodes
• Battery status - Though unlikely given recent implant context

The 2018 ACC/AHA/HRS bradycardia guidelines emphasize that pacemaker settings should be optimized for individual patient needs 7.

Semaglutide: Continue Current Regimen

Semaglutide 7.5 mg weekly should be continued without interruption. The patient has achieved excellent weight loss (down to 232 pounds over 6 months), and recent evidence demonstrates cardiovascular benefits:

• Cardiovascular safety is established - The SOUL trial showed oral semaglutide reduced major adverse cardiovascular events in high-risk type 2 diabetes patients 8
• Cardiac remodeling benefits - The STEP-HFpEF echocardiography substudy demonstrated semaglutide attenuates left atrial remodeling and improves diastolic function 9
• No contraindication with current medications - Semaglutide does not interact with metoprolol or affect pacemaker function

The weight loss achieved likely contributes to improved cardiovascular risk profile and may reduce AF burden long-term.

Lorazepam: Acceptable Bridge Therapy

The current lorazepam 0.5 mg PRN usage (5-6 times monthly) is reasonable as temporary symptom management while optimizing rate control, but this is treating the symptom, not the cause. The fact that palpitations resolve within one hour suggests:

• Anxiolytic effect reducing sympathetic tone
• Possible placebo effect
• Natural resolution of paroxysmal arrhythmia episodes

This pattern should decrease once metoprolol dosing is optimized. If lorazepam use increases or becomes daily, reassess the underlying arrhythmia control strategy.

Common Pitfalls to Avoid

1. Do not add dronedarone - Multiple guidelines contraindicate its use for rate control in permanent AF 1, 2, 1, 2, and it has significant drug interactions with metoprolol 5

2. Do not ignore the 22-hour symptom pattern - This is pharmacokinetic evidence of inadequate beta-blockade duration requiring dose adjustment or formulation change

3. Do not delay pacemaker interrogation - The pressure sensation is a red flag that requires device evaluation

4. Do not discontinue semaglutide - Weight loss and cardiovascular benefits support continuation 9, 8

5. Do not accept chronic benzodiazepine use - Lorazepam should be a bridge, not a long-term solution

Specific Action Plan

Within 1 week:

• Pacemaker interrogation with arrhythmia burden assessment
• Adjust metoprolol: either increase dose or switch to twice-daily tartrate formulation
• 24-hour Holter monitor to quantify arrhythmia burden and heart rate control

Within 1 month:

• Reassess symptoms and lorazepam usage
• Verify heart rate control at rest and with exertion
• Continue semaglutide 7.5 mg weekly

Do NOT add dronedarone at any point - contraindicated per guidelines and FDA label 1, 2, 1, 2, 3